In class we talked about the formation of VLDL lipoproteins in the liver. The as

Question

In class we talked about the formation of VLDL lipoproteins in the liver. The assembly of VLDL particles within the liver involves a protein called microsomal triglyceride transfer protein (MTP), which is essential for the assembly of apolipoprotein B (apo-B) containing lipoproteins. Known inhibition of MTP prevents hepatic VLDL secretion by preventing VLDL production. Given this effect, drugs targeting MTP are of interest as potential drugs for hyperlipidemia (a condition with elevated levels of lipid and/or lipoproteins).

Would there be an added benefit to combination therapy (MTP inhibitor plus statin) for patients who are heterozygous FH? In your answer, you do not need to consider the effect of statins on the regulation of HMG-CoA reductase.

Explanation / Answer

Based on recent researches of (GD Norata - 2013): The MTP inhibitor lomitapide which has has completed phase III testing when combined with with statins can in a research on 480 patients with severe heterozygous FH to treatment have exhibited a linear LDL reduction.

Related Questions

Navigate

• Browse (All)
• Browse I
• Subjects

Integrity-first tutoring: explanations and feedback only — we do not complete graded work. Learn more.